Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype

Michiels, 2005, Prediction of cancer outcome with microarrays: a multiple random validation strategy, Lancet, 365, 488, 10.1016/S0140-6736(05)17866-0 Ginestier, 2002, Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers, Am J Pathol, 161, 1223, 10.1016/S0002-9440(10)64399-4 Tyers, 2003, From genomics to proteomics, Nature, 422, 193, 10.1038/nature01510 Torhorst, 2001, Tissue microarrays for rapid linking of molecular changes to clinical endpoints, Am J Pathol, 159, 2249, 10.1016/S0002-9440(10)63075-1 Jacquemier, 2005, Protein expression profiling identifies subclasses of breast cancer and prediets prognosis, Cancer Res, 65, 767, 10.1158/0008-5472.767.65.3 Camp, 2002, Automated subcellular localization and quantification of protein expression in tissue microarrays, Nat Med, 8, 1323, 10.1038/nm791 Camp, 2003, Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome, Cancer Res, 63, 1445 Korsching, 2002, Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis, Lab Invest, 82, 1525, 10.1097/01.LAB.0000038508.86221.B3 Nielsen, 2004, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res, 10, 5367, 10.1158/1078-0432.CCR-04-0220 Charafe-Jauffret, 2006, Gene expression profiling of breast cell lines identifies potential new basal markers, Oncogene, 25, 2273, 10.1038/sj.onc.1209254 Makretsov Nikita, 2004, Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma, Clin Cancer Res, 10, 6143, 10.1158/1078-0432.CCR-04-0429 Ribeiro-Silva, 2005, p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer, Histopathology, 47, 458, 10.1111/j.1365-2559.2005.02249.x Livasy, 2006, Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma, Mod Pathol, 9, 264, 10.1038/modpathol.3800528 Charpin, 2004, Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays, Clin Cancer Res, 10, 5815, 10.1158/1078-0432.CCR-04-0021 Dalès, 2005, Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: retrospective study in a series of 745 patients, Int J Cancer, 116, 734, 10.1002/ijc.20984 Dalès, 2004, Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105 and CD31 immunocytochemical expression, Hum Pathol, 35, 176, 10.1016/j.humpath.2003.10.008 Anfosso, 2001, Outside-in signaling pathway linked to CD146 engagement in human endothelial cells, J Biol Chem, 276, 1564, 10.1074/jbc.M007065200 Yan, 2003, A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth, Immunobiology, 102, 184 Beviglia, 1997, Expression of the c-met/HGF receptor in human breast carcinoma: correlation with tumor progression, Int J Cancer, 74, 301, 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E Tolgay Ocal, 2003, Tissue microarray–based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors, Cancer, 97, 1841, 10.1002/cncr.11335 Pennacchietti, 2003, Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene, Cancer Cell, 3, 347, 10.1016/S1535-6108(03)00085-0 Gasparini, 2005, Combination of antiangiogenic therapy with other anticancer therapies: results, challenges and open questions, J Clin Oncol, 23, 1295, 10.1200/JCO.2005.10.022 Pouysségur, 2006, Hypoxia signaling in cancer and approaches to enforce tumor regression, Nature, 441, 437, 10.1038/nature04871 Birchmeier, 2003, Met, metastasis, motility and more, Nat Rev Mol Cell Biol, 4, 915, 10.1038/nrm1261 Christensen, 2005, c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention, Cancer Lett, 225, 1, 10.1016/j.canlet.2004.09.044 Kalliomeni, 2001, Tissue microarray technology for high throughput molecular profiling of cancer, Hum Mol Genet, 10, 657, 10.1093/hmg/10.7.657 Charpin, 1994, Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to mRNA expression and to immunohistochemical prognostic indicators, J Natl Cancer Inst, 20, 1539, 10.1093/jnci/86.20.1539 Charpin, 1997, Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas, Hum Pathol, 28, 289, 10.1016/S0046-8177(97)90126-X Tuck, 1996, Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma, Am J Pathol, 148, 225 Yamashita, 1994, Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer, Cancer Res, 54, 1630 Matsumoto, 2003, NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics, Cancer Sci, 94, 321, 10.1111/j.1349-7006.2003.tb01440.x Lark, 2005, High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype, Mod Pathol, 18, 1289, 10.1038/modpathol.3800424 Christensen, 2003, A selective small molecule inhibitor of c-met kinase inhibits c-met–dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo, Cancer Res, 63, 7345 Trusolino, 2002, Scatter-factor and semaphorin receptors: cell signaling for invasive growth, Nature, 2, 289 Inoue, 2000, Paclitaxel enhances the effects of the anti–epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma, Clin Cancer Res, 6, 4874